Latest Headlines
-
CURIS System And AST Unite To Redefine Aseptic Fill-Finish Processing Technology
2/5/2024
CURIS System, an innovator in advanced decontamination technology, and AST, a leader in aseptic fill-finish processing technology, today announced a groundbreaking partnership. This collaboration marks a significant step forward in the pharmaceutical manufacturing industry, as the two companies combine technology to revolutionize the biodecontamination of aseptic fill-finish isolators using CURIS's disruptive vapor decontamination technology.
-
Novo Holdings To Acquire CDMO Catalent Pharma Solutions For $16.5 Billion
2/5/2024
Catalent, Inc. (NYSE: CTLT), a leader in enabling the development and supply of better treatments for patients worldwide, and Novo Holdings, a holding and investment company that is responsible for managing the assets and wealth of the Novo Nordisk Foundation, today announced that they have entered into a merger agreement under which Novo Holdings will acquire Catalent in an all-cash transaction that values Catalent at $16.5 billion on an enterprise value basis.
-
Solesis, Parent Company of Charter Medical, to Expand Single-use Manufacturing Capabilities into Costa Rica
2/2/2024
The site will expand capabilities to enable development in the fast-growing cardiovascular and advanced therapy markets.
- IDT Biologika Receives CDMO Leadership Awards 2024 In Six Categories 2/2/2024
-
Cleanroom Leader AES Clean Technology Announces New Vice President Of Construction
2/1/2024
A leading provider of high-performance cleanroom facilities, AES Clean Technology, has announced the appointment of John Costalas to its senior leadership team as Vice President of Construction.
-
Kite Receives U.S. FDA Approval of Manufacturing Process Change Resulting in Reduced Median Turnaround Time for Yescarta® CAR T-cell Therapy
1/30/2024
Kite, a Gilead Company (Nasdaq: GILD), today announced that the U.S. Food and Drug Administration (FDA) has approved a manufacturing process change resulting in a shorter manufacturing time for Yescarta® (axicabtagene ciloleucel). With this approval, Kite’s median turnaround time (TAT) in the U.S. is anticipated to be reduced from 16 days to 14 days. Median TAT is defined as time from leukapheresis, when a patient’s T cells are collected, to product release; manufacturing is
-
AbbVie Announces $223 Million Investment For New Biologics Manufacturing Facility In Singapore
1/29/2024
AbbVie (NYSE: ABBV) strengthened its manufacturing capabilities by breaking ground Thursday on a new US$223 million (S$301 million) expansion of its Singapore manufacturing facility. This new investment will add more than 100 jobs and new biologics manufacturing capacity to AbbVie's global network.
-
INTEPRHEX Puts Hot-Topic Science In 2024 Event Registration Now Open | Event Program Now Online
1/22/2024
The reimagined INTERPHEX Conference is designed to bring attendees together to solve their business challenges and to understand the science that is shaping their industries.
-
Cleanroom Leader AES Clean Technology Announces New Chief Revenue Officer
1/18/2024
A leading provider of high-performance cleanroom facilities, AES Clean Technology, has appointed Brian Weed as Chief Revenue Officer (CRO).
-
AST To Exhibit Aseptic Filling Technologies At Advanced Therapies Week
12/27/2023
AST has over 50 years of experience designing, manufacturing, and servicing innovative, high quality and highly automated processing equipment. Beginning in 2006, AST leveraged our experience and close customer relationships to revolutionize the aseptic fill/finish industry with the launch of the ASEPTiCell® development.